Zydus atadlife Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.
Tel. No.: (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com

							Statement of Results for the Quarter and Six Months Ended 30/09/2013							
Rupees in Lacs								Rupees in Lacs						
CONSOLIDATED											IPANY			
		Corresponding 3 months	Year to date	Year to date						Corresponding 3 months	Year to date	Year to date		
		ended	figures for the	figures for the		Sr. No.	Particulars			ended	figures for the	figures for the		
3 Months	Preceding 3	30/09/2012 in	current period	previous year	Previous year			3 Months	Preceding 3	30/09/2012 in	current period	previous year	Previous year	
ended	months ended	the previous	ended	ended	ended			ended	months ended	the previous	ended	ended	ended	
30/09/2013	30/06/2013	year	30/09/2013	30/09/2012	31/03/2013			30/09/2013	30/06/2013	year	30/09/2013	30/09/2012	31/03/2013	
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
						1	Income from operations							
173,750	164,633	154,469	338,383	309,133	628,484	1	Gross Sales	85,652	81,234	71,820	166,886	142,646	297,811	
3,925	3,888	3,219	7,813	6,273	12,959		Less: Excise Duty	1,656	1,532	1,801	3,188	3,072	6,157	
169,825	160,745	151,250	330,570	302,860	615,525	а	Net Sales	83,996	79,702	70,019	163,698	139,574	291,654	
4,854	2,960	3,514	7,814	11,346	20,252	b	Other operating income	14,503	13,108	17,201	27,611	38,096	75,921	
174,679	163,705	154,764	338,384	314,206	635,777	С	Total income from operations (net)	98,499	92,810	87,220	191,309	177,670	367,575	
	l			l		2	Expenses	1		l				
41,255	38,613	38,805	79,868	70,000	151,074	а	Cost of materials consumed	28,877	24,864	24,779	53,741	43,341	94,415	
29,612	21,062	25,235	50,674	44,941	89,917	b	Purchases of stock-in-trade	8,913	8,920	9,527	17,833	15,907	33,242	
(3,243)	(5,736)	(4,387)	(8,979)	(1,366)	(8,966)	с	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(367)	(2,422)	(2,242)	(2,789)	1,579	(905)	
27,297	26,310	22,915	53,607	45,990	90,423	d	Employee benefits expense	13,085	13,409	13,607	26,494	27,283	52,250	
5,176	4,712	4,366	9,888	8,763	18,474	e	Depreciation and amortisation expense	3,247	3,039	2,747	6,286	5,574	11,684	
53,704	54,877	49,140	108,581	95,842	200,823	f	Other expenses	30,985	30,473	29,748	61,458	55,693	117,943	
153,801	139,838	136,074	293,639	264,170	541,745	9	Total expenses	84,740	78,283	78,166	163,023	149,377	308,629	
20,878	23,867	18,690	44,745	50,036	94,032	3	Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	13,759	14,527	9,054	28,286	28,293	58,946	
1,223	1,253	646	2,476	1,597	3,701	4	Other income	870	21,954	2,521	22,824	2,915	5,292	
22,101	25,120	19,336	47,221	51,633	97,733	5	Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	14,629	36,481	11,575	51,110	31,208	64,238	
1,933	2,784	4,050	4,717	9,769	16,867	6	Finance costs	1,010	1,460	2,803	2,470	6,682	11,102	
20,168	22,336	15,286	42,504	41,864	80,866	7	Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	13,619	35,021	8,772	48,640	24,526	53,136	
0	0	0	0	0	0	8	Exceptional items	0	0	0	0	0	0	
20,168	22,336	15,286	42,504	41,864	80,866	9	Profit/ (Loss) from ordinary activities before tax (7+8)	13,619	35,021	8,772	48,640	24,526	53,136	
1,011	2,031	4,939	3,042	11,476	11,877	10	Tax expense	(1,557)	999	414	(558)	1,610	3,281	
19,157	20,305	10,347	39,462	30,388	68,989	11	Net Profit/ (Loss) from ordinary activities after tax (9-10)	15,176	34,022	8,358	49,198	22,916	49,855	
0	0	0	0	0	0	12	Extraordinary items (net of tax expense)	0	0.,,,,,	0	0	0	0	
19,157	20,305	10,347	39,462	30,388	68,989	13	Net Profit/ (Loss) for the period (11-12)	15,176	34,022	8,358	49,198	22,916	49,855	
0	0	0	0.,	0	0	14	Share of profit/ (loss) of associates	0	0.,,,,,	0	0	0	0	
(820)	(799)	(883)	(1,619)	(1,497)	(3,643)	15	Minority interest	0	0	0		0	0	
18,337	19,506	9,464	37,843	28,891	65,346	16	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	15,176	34.022	8.358	49,198	22.916	49.855	
	.,,,,,,,		- 7							.,	.,		.,	
10,237	10,237	10,237	10,237	10,237	10,237	17	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237	10,237	10,237	
						18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						280,912	
						19 i	Earnings per share (before extraordinary items)							
	l			l			(of Rs. 5/- each) (not annualised):	1		l				
8.96	9.53	4.62	18.48	14.11	31.92	а	Basic (Rs.)	7.41	16.62	4.08	24.03	11.19	24.35	
8.96	9.53	4.62	18.48	14.11	31.92	b	Diluted (Rs.)	7.41	16.62	4.08	24.03	11.19	24.35	
1	1		l	1		19 ii	Earnings per share (after extraordinary items)	1		1	l			
	l			l			(of Rs. 5/- each) (not annualised):	1		l				
8.96	9.53	4.62	18.48	14.11	31.92	a	Basic (Rs.)	7.41	16.62	4.08	24.03	11.19	24.35	
8.96	9.53	4.62	18.48	14.11	31.92	b	Diluted (Rs.)	7.41	16.62	4.08	24.03	11.19	24.35	
Motor I														

Notes:

- The above results for the quarter six morths ended on September 30, 2013 were reviewed by the Audit Committee on October 30, 2013 and then approved by the Board of Directors at their meeting held on October 31, 2013.

 The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Clause 41 of the Listing Agreement.

 The Scheme of Amalgamation of the Healthcare Limited, 27,drs. Animal Health Limited and 27,drs. Palmanisacuticials Limited with the Company from the appointed date of April 1, 2012, has been sanctioned by the horibate help Court of Calignat. Pursuant to the Scheme becoming effective on August 26, 2013, the figures for the previous quarter/six mornths have been recast for the purpose of meaningful companis on with the figures of the current quarter size smorth.

 The Company has incorporated Lian Phermaceuticals Limited as a wholly onned subsidiary company, in the state of Gujarat on October 4, 2013.

 The changes in investments during the quarter are as under:

 27,dust international Private Limited (additional investments) Rs. 5,278 Lacs
 27,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 28,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 29,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharma Private Limited (additional investments) Rs. 5,278 Lacs
 20,dust 80V Pharm [2] [3]

- [6]

			1	,			Select information for the Quarter and Six Months Ended 30/09/2013						
3 Months ended	Preceding 3 months ended	3 months ended 30/09/2012 in the previous	Year to date figures for the current period ended	Year to date figures for the previous year ended	Previous year ended		Particulars	3 Months ended	Preceding 3 months ended	3 months ended 30/09/2012 in the previous	Year to date figures for the current period ended	Year to date figures for the previous year ended	Previous yea
30/09/2013	30/06/2013	vear	30/09/2013	30/09/2012	31/03/2013	A	PARTICULARS OF SHAREHOLDING	30/09/2013	30/06/2013	vear	30/09/2013	30/09/2012	31/03/2013
51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	1	Public shareholding - Number of shares	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,47
25.21%	25.21%	25.21%	25.21%	25.21%	25.21%		- Number of Shareholding - Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%	25.21%	25.21
						2	Promoters and Promoter Group Shareholding						
						a	Pledged / Encumbered						
Nil N.A.	Nil N.A.	NII N.A.	Nil N.A.	Nil N.A.	Nil N.A.		Number of shares Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil N.A.	NA.	NA.	Nil N.A.	Nil N.A.	N
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.		Percentage of shares (as a % of the total share capital of the company)	N.A.	N.A.	N.A.	N.A.	N.A.	N N
						b	Non - encumbered						
153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046		- Number of shares	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,04
100.00%	100.00%	100.00%	100.00%	100.00%	100.00%		- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00
74.79%	74.79%	74.79%	74.79%	74.79%	74.79%		- Percentage of shares (as a % of the total share capital of the company)	74.79%	74.79%	74.79%	74.79%	74.79%	74.79
				!			!	+					
							Particulars	3 months ended					
								30/09/2013					
						В	INVESTOR COMPLAINTS (In Numbers) Pending at the beginning of the quarter	Nil					
							Received during the quarter	10					
							Disposed of during the quarter	10					
							Remaining unresolved at the end of the quarter	Nil					
				CONSO	LIDATED		Statement of Assets and Liabilities	СОМ	PANY				
CONSOLIDATED Rupees in Lacs									in Lacs				
				As at current	As at previous		Particulars	As at current	As at previous				
				half year end	year end		i dictalal	half year end	year end				
				30/09/2013 (Unaudited)	31/03/2013 (Audited)			30/09/2013 (Unaudited)	31/03/2013 (Audited)				
							EQUITY AND LIABILITIES						
							Shareholders' funds						
				10,237 306.828	10,237 284 209		Share capital Reserves and surplus	10,237	10,237 280,912				
				317,065	294,446		Sub-total - Shareholders' funds	340,025	291,149				
				13,529	11,933	2	Minority Interest	0	0				
							Non-current liabilities						
				156,460	142,602		Long-term borrowings Deferred tax liabilities (net)	91,593	79,412				
				9,024 4,369	10,046 4,696		Other long-term liabilities	12,364 2,164	12,364 2.716				
				6,342	6,448		Long-term provisions	3,239	3,278				
				176,195	163,792		Sub-total - Non-current liabilities	109,360	97,770				
							Current liabilities Short-term hormwings						
				138,216 82,978	125,708 65,683		Short-term borrowings Trade payables	94,574 43,483	85,143 36,072				
				61,544	50,919		Other current liabilities	43,483 26,129	26,951				
				7,609	24,735		Short-term provisions	389	17,915				
				290,347	267,045		Sub-total - Current liabilities	164,575	166,081				
				797,136	737,216	R	TOTAL - EQUITY AND LIABILITES ASSETS	613,960	555,000				
						1							
				328,459	300,397		Fixed assets	210,151	196,087				
				74,817	75,726			0	0				
				2,115	2,115	١ '	Non-current investments	114,084	106,396				
				45,494	39,809	:	Long-term loans and advances Other non-current assets	82,291	71,674				
				450,885	418,047	1 '	Sub-total - Non-current assets	406,526	374,157				
						2	Current assets						
				2,476	9,332		Current investments	23.237	21.593				
							Inventories	66.061	58.724				
				136,852	121,357								
				117,293	95,514		Trade receivables	80.496 12.484	68.296 9.164				
					95,514 58,377			80.496 12.484 21.852	68.296 9.164 19.099				
				117,293 54,516	95,514		Trade receivables Cash and cash equivalents	12.484	9.164				
				117,293 54,516 29,742	95,514 58,377 27,896		Trade receivables Cash and cash equivalents Short-term loans and advances	12.484 21.852	9.164 19.099				

By Order of the Board, For Cadila Healthcare Limited,

Pankaj R. Pate Chairman & Managing Director

medabad, October 31, 2013